3-羟基邻苯二甲酸二甲酯 | 36669-02-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-羟基邻苯二甲酸二甲酯
• 英文名称: dimethyl 3-hydroxyphthalate
• 英文别名: 3-Hydroxyphthalsaeure-dimethylester；2,3-bis(methoxycarbonyl)phenol；dimethyl 3-hydroxybenzene-1,2-dicarboxylate
• CAS: 36669-02-0
• 化学式: C₁₀H₁₀O₅
• 分子量: 210.186
• InChiKey: BQGDDMMXPRJQHZ-UHFFFAOYSA-N

物化性质

• 熔点：
  54-55 °C
• 沸点：
  94-96 °C(Press: 0.1 Torr)
• 密度：
  1.284±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于乙腈（少量）、氯仿（少量）、甲醇（少量）
• 保留指数：
  1500

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 储存条件：
  存储条件：2-8°C，密封保存，置于干燥处。

反应信息

• 作为反应物：
  描述：

  3-羟基邻苯二甲酸二甲酯 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、303.98 kPa 条件下， 反应 27.0h， 生成 dimethyl 3-[4-methoxycarbonyl-2-(4-octadecanoylaminobenzoylamino)phenoxy]phthalate
  参考文献：
  名称：

  Studies on selectin blocker. 9. SARs of non-sugar selectin blocker against E-, P-, L-selectin bindings

  摘要：

  As a part of study of selectin blockers, we have already reported that a non-sugar selectin antagonist (3) was successfully discovered using a computational screening (Hiramatsu, Y.; Tsukida, T.; Nakai, Y.; Inoue, Y.; Kondo, H. J. Med. Chem. 2000, 43 1476). To investigate the SARs of compound 3 against E-, P-, and L-selectins, we synthesized the derivatives of compound 3 and evaluated their inhibitory activities toward selectin bindings. The structural diversity of compound 3 contained the following. (1) a modification of the spacer unit (4-7), (2) a modification of the tail unit (8-11), (3) a modification of the head unit (12-18). As a result, it was found that a non-sugar based selectin blocker (3) could be a potential lead compound for E-, P-, and L-selectin blockers and some of the derivatives showed broad and/or selective inhibitory activities toward the E-, P-, and L-selectins. In addition, it was found that the experimental evidence well supported that the computational screening using 3D-pharmacophore model could be useful methodology to find out a new lead for the several type of selectin blockers, which included a broad and/or a selective inhibitor. (C) 2001 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(01)00023-2
• 作为产物：
  描述：

  3-羟基苯二甲酸酐 在 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 3-羟基邻苯二甲酸二甲酯
  参考文献：
  名称：

  [EN] CLIPTAC COMPOSITION
  [FR] COMPOSITION CLIPTAC

  摘要：

  这项发明涉及通过生物正交点击化学（CLIPTACs）形成的前体的细胞内自组装的蛋白水解靶向嵌合分子，以及相关的前体组合物、方法和治疗应用。

  公开号：

  WO2017212329A1

文献信息

• METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20160176916A1

  公开（公告）日：2016-06-23

  The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.

  本申请提供了作为蛋白质降解诱导基团的双功能化合物。本申请还涉及通过使用将结合脑白质蛋白的基团与能够结合到靶向蛋白的配体相连的双功能化合物来实现内源蛋白的靶向降解的方法，该方法可用于治疗增殖性疾病。本申请还提供了制备本申请化合物及其中间体的方法。
• Compounds and pharmaceutical use thereof
  申请人：Japan Tobacco Inc.

  公开号：US06017919A1

  公开（公告）日：2000-01-25

  The compounds of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The Compound (I) and pharmaceutically acceptable salts thereof of the present invention selectively act on cannabinoid receptors, particularly peripheral receptors, cause less side effects on the central system, and have superior immunoregulating action, antiinflammatory action, antiallergic action and therapeutic effect on nephritis. Therefore, they are useful as cannabinoid receptor, particularly peripheral cannabinoid receptor activators and antagonists, immunoregulators, therapeutic agents for autoimmune diseases, antiinflammatory agents, antiallergic agents and therapeutic agents for nephritis.

  公式（I）##STR1##中的化合物，其中每个符号如说明书中所定义，其药用可接受的盐及其医药用途。本发明的化合物（I）及其药用可接受的盐对大麻素受体具有选择性作用，尤其是外周受体，对中枢系统的副作用较小，并且具有卓越的免疫调节作用、抗炎作用、抗过敏作用和对肾炎的治疗效果。因此，它们作为大麻素受体，尤其是外周大麻素受体的激动剂和拮抗剂，免疫调节剂，自身免疫性疾病的治疗剂，抗炎剂，抗过敏剂和肾炎的治疗剂是有用的。
• [EN] REGULATING CHIMERIC ANTIGEN RECEPTORS<br/>[FR] RÉGULATION DE RÉCEPTEURS D'ANTIGÈNES CHIMÉRIQUES
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2018148440A1

  公开（公告）日：2018-08-16

  This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.

  这项发明涉及用于调节嵌合抗原受体免疫效应细胞（例如T细胞（CAR-T））治疗以调节相关的不良炎症反应的组合物和方法，例如细胞因子释放综合征和肿瘤溶解综合征，通过靶向蛋白质降解。
• [EN] TUNABLE ENDOGENOUS PROTEIN DEGRADATION WITH HETEROBIFUNCTIONAL COMPOUNDS<br/>[FR] DÉGRADATION MODULABLE DE PROTÉINE ENDOGÈNE AVEC DES COMPOSÉS HÉTÉROBIFONCTIONNELS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2018148443A1

  公开（公告）日：2018-08-16

  The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.

  本发明提供了一种在体内调节基因表达的方法，避免了与CRISPR内源蛋白敲除或敲入策略以及提供单个核苷酸修正或改变的策略相关的问题。该发明包括将编码靶向蛋白（dTAG）的异双功能化合物的核苷酸插入基因组中，与编码感兴趣的内源表达蛋白的基因的核苷酸序列同框，表达后产生内源蛋白-dTAG杂交蛋白。这允许使用异双功能化合物对dTAG和融合的内源蛋白进行靶向蛋白降解。
• From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
  作者：James W. Papatzimas、Evgueni Gorobets、Ranjan Maity、Mir Ishruna Muniyat、Justin L. MacCallum、Paola Neri、Nizar J. Bahlis、Darren J. Derksen

  DOI：10.1021/acs.jmedchem.9b00455

  日期：2019.6.13

  interactions (PPIs) have emerged as significant targets for therapeutic development, owing to their critical nature in diverse biological processes. An ideal PPI-based target is the protein myeloid cell leukemia 1 (MCL1), a critical prosurvival factor in cancers such as multiple myeloma where MCL1 levels directly correlate to disease progression. Current strategies for halting the antiapoptotic properties

  由于蛋白质-蛋白质相互作用（PPI）在多种生物学过程中的关键性质，它们已成为治疗发展的重要目标。理想的基于PPI的靶标是蛋白质髓样细胞白血病1（MCL1），它是癌症（例如多发性骨髓瘤）中的关键生存因子，其中MCL1水平直接与疾病进展相关。停止MCL1抗凋亡特性的当前策略围绕抑制其螯合促凋亡因子而展开。现有的抑制剂会破坏内源性调节蛋白。但是，这种策略实际上导致MCL1蛋白水平的提高。在这里，我们展示了能够使用成功靶向降解的蛋白水解靶向嵌合体（PROTAC）方法选择性靶向MCL1的异双功能小分子的发展。